Floatz logo

Vidutolimod

Clinical Stage III Cutaneous Melanoma AJCC v8

National Cancer Institute (NCI)nucleic_acidPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the Clinical Stage III Cutaneous Melanoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Ipilimumab
Amsterdam UMC, location VUmc
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Atezolizumab
EuroCityClinic LLC
Phase 2BB
INTERFERON ALFA-2B
National Cancer Institute (NCI)
Phase 3B
Tocilizumab
M.D. Anderson Cancer Center
Phase 2B

View all 38 →

Same molecule, other indications

Vidutolimod is also rated in:

melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic melanomaDormant
CCC
Indicative ·
49 / 100
View asset →
lymph node cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →